TScan Therapeutics, Inc.
NASDAQ:TCRX
2.63 (USD) • At close January 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 21.049 | 13.535 | 10.141 | 1.085 | 0 |
| Cost of Revenue
| 88.153 | 5.137 | 3.328 | 20.577 | 0.519 |
| Gross Profit
| -67.104 | 8.398 | 6.813 | -19.492 | -0.519 |
| Gross Profit Ratio
| -3.188 | 0.62 | 0.672 | -17.965 | 0 |
| Reseach & Development Expenses
| 88.153 | 59.819 | 44.954 | 20.577 | 9.442 |
| General & Administrative Expenses
| 26.354 | 20.352 | 13.828 | 6.741 | 4.768 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 |
| SG&A
| 26.354 | 20.352 | 13.828 | 6.741 | 4.768 |
| Other Expenses
| 0 | 1.591 | 0.016 | 0 | 0 |
| Operating Expenses
| 114.507 | 80.171 | 58.782 | 27.318 | 14.21 |
| Operating Income
| -93.458 | -66.636 | -48.641 | -26.233 | -14.21 |
| Operating Income Ratio
| -4.44 | -4.923 | -4.796 | -24.178 | 0 |
| Total Other Income Expenses Net
| 4.24 | 0.415 | 0.016 | 0.106 | 0.552 |
| Income Before Tax
| -89.218 | -66.221 | -48.625 | -26.127 | -13.658 |
| Income Before Tax Ratio
| -4.239 | -4.893 | -4.795 | -24.08 | 0 |
| Income Tax Expense
| 0 | -0.415 | 3.091 | -0.106 | -0.552 |
| Net Income
| -89.218 | -65.806 | -48.625 | -26.021 | -13.106 |
| Net Income Ratio
| -4.239 | -4.862 | -4.795 | -23.982 | 0 |
| EPS
| -1.36 | -2.74 | -2.03 | -1.04 | -0.53 |
| EPS Diluted
| -1.36 | -2.74 | -2.03 | -1.04 | -0.53 |
| EBITDA
| -80.098 | -59.908 | -45.297 | -25.003 | -13.691 |
| EBITDA Ratio
| -3.805 | -4.806 | -4.468 | -23.044 | 0 |